English Français Español 中文 العربية

Eventos Noticias Análisis Organizadores

Marketing de EventosPublica, promociona y haz crecer tus eventos ante una audiencia B2B global.
Comunicado de PrensaDistribuye anuncios oficiales a profesionales del sector en todo el mundo.
Promoción de Ponentes y ExpertosMuestra tu experiencia y consigue keynotes, paneles y masterclasses.

Acceso Ponentes Publicar su evento gratis

La plataforma de descubrimiento de eventos B2B más confiable del mundo. Conectamos a los profesionales del sector con las conferencias, exposiciones y cumbres que importan.

Industry Events
Noticias
Organizadores de eventos
Acerca de nosotros
Nuestros servicios
Organizador Premium
Event Pro
Conviértete en Ponente
Suscribirse

Términos
Privacidad

© 2026 Industry Events Worldwide. Todos los derechos reservados.

VF96.7.

Eventos
Noticias
Análisis
Cuenta

English Français Español 中文 العربية

Eventos Noticias Análisis Organizadores

Marketing de EventosPublica, promociona y haz crecer tus eventos ante una audiencia B2B global.
Comunicado de PrensaDistribuye anuncios oficiales a profesionales del sector en todo el mundo.
Promoción de Ponentes y ExpertosMuestra tu experiencia y consigue keynotes, paneles y masterclasses.

Acceso Ponentes Publicar su evento gratis

News

Categories

Últimas
Agricultura
Cadena de Suministro
China y BRICS+
Ciberseguridad
Defensa
Energía y Movilidad
Fintech
IA y Tecnología
Robótica
Salud
Semiconductores
Startups y Capital Riesgo

Select a category to explore the latest industry reporting.

NewsWednesday, 26 August 2026

Newsletter subscribe · Free

Buscar noticias

Últimas
IA y Tecnología
Ciberseguridad
Semiconductores
Robótica
Fintech
Energía y Movilidad
Defensa
Salud
Cadena de Suministro
Startups y Capital Riesgo
China y BRICS+
Agricultura

Noticias

Salud

Las últimas noticias, anuncios y análisis del sector Salud, provenientes de las conferencias, exposiciones y cumbres que dan forma al sector.

Últimas noticias de la sección

STAT+: Skylark Bio kicks off new gene therapy trial for deafness

(opens original source in a new tab)

STAT News

STAT+: Skylark Bio kicks off new gene therapy trial for deafness

La plataforma de descubrimiento de eventos B2B más confiable del mundo. Conectamos a los profesionales del sector con las conferencias, exposiciones y cumbres que importan.

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.

(opens original source in a new tab)

O. Rose Broderick·11 August 2026

STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?

(opens original source in a new tab)

STAT News

STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?

Biotech companies don’t hide or obfuscate strong data.

(opens original source in a new tab)

Adam Feuerstein·11 August 2026

Trump returns to controversial vaccine policy with order questioning childhood schedule

(opens original source in a new tab)

STAT News

Trump returns to controversial vaccine policy with order questioning childhood schedule

The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.

(opens original source in a new tab)

Daniel Payne·10 August 2026

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

(opens original source in a new tab)

STAT News

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

(opens original source in a new tab)

Allison DeAngelis·10 August 2026

FDA to require notice of additives in food supply for the first time

(opens original source in a new tab)

STAT News

FDA to require notice of additives in food supply for the first time

RFK Jr. is claiming a win with a new proposal on the food industry's GRAS loophole; nutrition advocates give mixed reviews.

(opens original source in a new tab)

Isabella Cueto and Elizabeth Cooney·10 August 2026

STAT+: Ban prior auth? And hospitals cut jobs

(opens original source in a new tab)

STAT News

STAT+: Ban prior auth? And hospitals cut jobs

We examine a call to reform how health insurers do business, and a look at the impact of 340B restrictions.

(opens original source in a new tab)

Bob Herman·10 August 2026

STAT+: FDA panel to weigh Grail’s Galleri test

(opens original source in a new tab)

STAT News

STAT+: FDA panel to weigh Grail’s Galleri test

China reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readout

(opens original source in a new tab)

Meghana Keshavan·10 August 2026

STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

(opens original source in a new tab)

STAT News

STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues

(opens original source in a new tab)

Ed Silverman·10 August 2026

STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

(opens original source in a new tab)

STAT News

STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.

(opens original source in a new tab)

Jason Mast·10 August 2026

STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study

(opens original source in a new tab)

STAT News

STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study

A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.

(opens original source in a new tab)

Adam Feuerstein·10 August 2026

STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer

(opens original source in a new tab)

STAT News

STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer

A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.

(opens original source in a new tab)

Jason Mast·10 August 2026

STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed

(opens original source in a new tab)

STAT News

STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed

China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some Americans, too.

(opens original source in a new tab)

Brian Yang·10 August 2026

Los más leídos

STAT+: Skylark Bio kicks off new gene therapy trial for deafness
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
Trump returns to controversial vaccine policy with order questioning childhood schedule
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
FDA to require notice of additives in food supply for the first time

8
9
10
11
12
13
14

Industry Events
Noticias
Organizadores de eventos
Acerca de nosotros
Nuestros servicios
Organizador Premium
Event Pro
Conviértete en Ponente
Suscribirse

Términos
Privacidad

© 2026 Industry Events Worldwide. Todos los derechos reservados.

VF96.7.

La semana en eventos de la industria, entregada cada viernes.

Un email corto. Las mejores historias de ferias, conferencias y cumbres que dan forma a los negocios mundiales. Sin relleno, sin spam, cancela en cualquier momento.

Sitio web

¿En qué sector trabaja? (opcional — nos ayuda a personalizar su resumen)